open access

Vol 89, No 5 (2021)
Case report
Submitted: 2021-01-16
Accepted: 2021-05-20
Published online: 2021-09-27
Get Citation

Nintedanib-mediated improvement in CT imaging in pulmonary fibrosis associated with systemic scleroderma

Kengo Nishino1, Yuika Sasatani1, Gen Ohara1, Katsunori Kagohashi1, Hiroaki Satoh1
DOI: 10.5603/ARM.a2021.0072
·
Pubmed: 34569613
·
Adv Respir Med 2021;89(5):528-531.
Affiliations
  1. Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Japan

open access

Vol 89, No 5 (2021)
CASE REPORTS
Submitted: 2021-01-16
Accepted: 2021-05-20
Published online: 2021-09-27

Abstract

Nintedanib is an antifibrotic drug that has an inhibitory effect on growth factor tyrosine kinases. In patients with idiopathic pulmonary fibrosis and systemic scleroderma-associated interstitial pneumonia (SSc-IP), nintedanib has been effective in suppressing the decline in forced vital capacity over time and the onset of acute exacerbation of interstitial pneumonia. Here, we report a SSc-IP patient who showed an improvement on CT images following nintedanib treatment. To our knowledge, this is the first report of such a case. Although SSc-IP patients are very rare, additional clinical experience and understanding will be required to prove the therapeutic benefit of nintedanib in these cases in relation to improved chest images.

Abstract

Nintedanib is an antifibrotic drug that has an inhibitory effect on growth factor tyrosine kinases. In patients with idiopathic pulmonary fibrosis and systemic scleroderma-associated interstitial pneumonia (SSc-IP), nintedanib has been effective in suppressing the decline in forced vital capacity over time and the onset of acute exacerbation of interstitial pneumonia. Here, we report a SSc-IP patient who showed an improvement on CT images following nintedanib treatment. To our knowledge, this is the first report of such a case. Although SSc-IP patients are very rare, additional clinical experience and understanding will be required to prove the therapeutic benefit of nintedanib in these cases in relation to improved chest images.

Get Citation

Keywords

systemic scleroderma, pulmonary fibrosis, nintedanib, computed tomography

About this article
Title

Nintedanib-mediated improvement in CT imaging in pulmonary fibrosis associated with systemic scleroderma

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 5 (2021)

Article type

Case report

Pages

528-531

Published online

2021-09-27

DOI

10.5603/ARM.a2021.0072

Pubmed

34569613

Bibliographic record

Adv Respir Med 2021;89(5):528-531.

Keywords

systemic scleroderma
pulmonary fibrosis
nintedanib
computed tomography

Authors

Kengo Nishino
Yuika Sasatani
Gen Ohara
Katsunori Kagohashi
Hiroaki Satoh

References (14)
  1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013; 65(11): 2737–2747.
  2. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007; 66(6): 754–763.
  3. Elhai M, Meune C, Boubaya M, et al. EUSTAR group. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012; 51(6): 1017–1026.
  4. Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2071–2082.
  5. Collard HR, Richeldi L, Kim DS, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2071–2082.
  6. Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019; 7(1): 60–68.
  7. Maher TM, Mayes MD, Kreuter M, et al. SENSCIS Trial Investigators. Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021; 73(4): 671–676.
  8. Ito Y, Tazaki G, Kondo Y, et al. Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases. Respir Med Case Rep. 2019; 26: 317–320.
  9. Nakano A, Ohkubo H, Fukumitsu K, et al. Remarkable improvement in a patient with idiopathic pulmonary fibrosis after treatment with nintedanib. Intern Med. 2019; 58(8): 1141–1144.
  10. Tomioka H, Takata H. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis. Respirol Case Rep. 2017; 5(2): e00215.
  11. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68(12): 4774–4782.
  12. Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019; 38(10): 2673–2681.
  13. Hachula E, Hamblin M, Ogura T et al. Changes in imaging markers in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with nintedanib: Sub-study of the SENSCIS Trial. Abstract Number: 1382, ACR Convergence 2020. https://acrabstracts.org/abstract/changes-in-imaging-markers-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-treated-with-nintedanib-sub-study-of-the-senscis-trial/.
  14. Schneider PD, Wise RA, Hochberg MC, et al. Serial pulmonary function in systemic sclerosis. Am J Med. 1982; 73(3): 385–394.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl